Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients
Status:
Completed
Trial end date:
2017-02-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to collect safety clinical data in HIV-infected pediatric
patients aged 6 and older to younger than18 years and weighing 15 kg or more, who are
receiving atazanavir capsule boosted with ritonavir and an optimized nucleoside reverse
transcriptase inhibitor backbone therapy as part of their antiretroviral regimen.